Engine Biosciences任命知名药物发现与开发领军人物 Robert Abraham博士为首席科学官-动脉网

Engine Biosciences Appoints Renowned Drug Discovery and Development Leader Robert Abraham, PhD, as Chief Scientific Officer

CISION 等信源发布 2025-04-30 20:00



可切换为仅中文







Global expert's appointment further strengthens Engine's scientific and R&D leadership as the company advances its precision oncology pipeline toward the clinic

全球专家的任命进一步加强了Engine公司在科学和研发方面的领导地位，因为该公司正在推进其精准肿瘤学产品线走向临床。

SINGAPORE

新加坡

and

和

REDWOOD CITY, Calif.

加利福尼亚州红木城

，

April 30, 2025

2025年4月30日

/PRNewswire/ -- Engine Biosciences (Engine), a company pioneering cancer medicines informed by its proprietary machine learning and functional genomics platform, today announced the appointment of

/PRNewswire/ -- Engine Biosciences（Engine），一家通过其专有的机器学习和功能基因组学平台推动癌症药物研发的公司，今天宣布任命

Robert (Bob) Abraham

罗伯特（鲍勃）亚伯拉罕

, PhD, as Chief Scientific Officer (CSO). Dr. Abraham brings over three decades of experience leading scientific and translational efforts in oncology and joins Engine as the company advances its drug discovery and development programs.

，博士，担任首席科学官（CSO）。亚伯拉罕博士在肿瘤学领域的科学和转化工作方面拥有三十多年的经验，并在Engine公司推进其药物发现和开发项目之际加入该公司。

'Bob's career reflects an extraordinary track record in translating science into therapeutics and patient impact,' said

“鲍勃的职业生涯反映了将科学转化为治疗和患者影响的非凡记录，”

Jeffrey Lu

杰弗里·卢

, Co-Founder and CEO of Engine Biosciences. 'His deep expertise in oncology drug discovery and development, and his leadership of world-class R&D organizations, are a great match for our platform and pipeline rooted in innovative science and significant clinical potential. We're thrilled to welcome him as we drive to deliver our mission to bring highly impactful precision medicines to patients.'.

Engine Biosciences的联合创始人兼首席执行官。“他在肿瘤药物发现和开发方面的深厚专业知识，以及对世界级研发组织的领导能力，与我们基于创新科学和巨大临床潜力的平台和管线非常契合。我们很高兴欢迎他加入，共同致力于实现为患者带来高影响力的精准药物的使命。”

'I am incredibly excited to join the talented Engine team,' said Dr.

“我非常激动能够加入才华横溢的Engine团队，”博士说道。

Robert Abraham

罗伯特·亚伯拉罕

. 'I look forward to leveraging the company's outstanding capabilities in high-throughput genomics and machine learning to identify and address novel cancer dependencies and biomarkers, with the singular goal of delivering meaningful medicines to precisely targeted populations of cancer patients.'

“我期待利用公司在高通量基因组学和机器学习方面的卓越能力，识别和解决新的癌症依赖性和生物标志物，唯一目标是为精确锁定的癌症患者群体提供有意义的药物。”

Over the course of a career spanning biotech, pharma and academia, Dr. Abraham has contributed to the development of 11 FDA-approved oncology drugs. He most recently served as Executive Vice President and Head of Cancer Biology at Odyssey Therapeutics and previously as Chief Scientific Officer at Vividion Therapeutics (acquired by Bayer).

在横跨生物技术、制药和学术界的职业生涯中，亚伯拉罕博士为11种FDA批准的肿瘤药物的开发做出了贡献。他最近担任奥德赛治疗公司的执行副总裁兼癌症生物学主管，之前任维维迪恩治疗公司（被拜耳收购）的首席科学官。

In a decade at Pfizer, Dr. Abraham served as Senior Vice President and Worldwide Head of the Oncology R&D group, where he led global cancer drug discovery and early clinical development to deliver impactful cancer medicines. He joined Pfizer following the acquisition of Wyeth, where he served as Head of Oncology Discovery Research..

在辉瑞工作的十年间，亚伯拉罕博士担任高级副总裁兼肿瘤学研发部门的全球负责人，领导全球癌症药物的发现和早期临床开发，以提供有影响力的抗癌药物。他是在辉瑞收购惠氏后加入公司的，此前他在惠氏担任肿瘤学发现研究部门的负责人。

Dr. Abraham has held academic appointments at the Mayo Clinic,

亚伯拉罕博士曾在梅奥诊所担任学术职务，

Duke University

杜克大学

, and the Sanford-Burnham-Prebys Medical Discovery Institute. He has authored more than 230 scientific publications with over 59,000 citations and is recognized globally for his work in cancer biology, immunology, and signal transduction. He earned his PhD in Pharmacology from the

，以及桑福德-伯纳姆-普雷比斯医学发现研究所。他已经发表了230多篇科学出版物，被引用超过59,000次，并因其在癌症生物学、免疫学和信号转导方面的工作而受到全球认可。他获得了 pharmacology博士学位

University of Pittsburgh

匹兹堡大学

and completed postdoctoral training at the Mayo Clinic.

并在梅奥诊所完成博士后培训。

Engine Biosciences NetMAPPR platform integrates AI, functional genomics, and translational science to uncover and prosecute key genetic interactions and tumor-specific vulnerabilities. Leveraging NetMAPPR, Engine has assembled the largest-known synthetic lethality knowledge base. With multiple programs in internal and partnered development, the company is building and advancing a pipeline of potential first-in-class and best-in-class precision oncology therapeutics aimed at addressing significant unmet needs..

Engine Biosciences的NetMAPPR平台整合了人工智能、功能基因组学和转化科学，以揭示并利用关键的基因相互作用和肿瘤特异性弱点。通过NetMAPPR，Engine构建了已知最大的合成致死知识库。公司内部和合作开发的多个项目正在进行中，致力于打造和推进潜在的首创新药和同类最佳精准肿瘤治疗药物管线，以满足显著未被满足的医疗需求。

About Engine Biosciences

关于引擎生物科学

Engine Biosciences (Engine) is a venture-backed

Engine Biosciences（Engine）是一家风险投资支持的

Singapore

新加坡

and Silicon Valley based company discovering and developing impactful precision medicines by deciphering complex biology with integrated computation and experimentation, with particular depth in oncology gained over several years of substantial investment and focus. Having pinpointed many promising drug targets and predictive biomarkers for patients most likely to benefit, Engine is advancing its pipeline of oncology therapeutics towards the clinic internally and with collaborators, and in other disease areas through partnerships.

一家位于硅谷的公司，通过整合计算和实验来解读复杂生物学，从而发现并开发具有影响力的精准药物，在多年大量投资和专注下，尤其在肿瘤学领域有深厚积累。在确定了许多前景广阔的药物靶点和预测性生物标志物，针对最可能受益的患者后，Engine正在内部及与合作伙伴一起推动其肿瘤治疗产品管线进入临床，并通过合作在其他疾病领域开展工作。

Engine's team is motivated by opportunities to address significant unmet needs with more selective and effective precision medicines. For more information, please visit .

引擎团队受到利用更具选择性和有效性的精准药物来满足重大未满足需求的机会的激励。欲了解更多信息，请访问。

www.enginebio.com

, and follow Engine on

，关注引擎

领英

。

Contacts

联系人

Media:

媒体：

Media at Engine Biosciences

引擎生物科学媒体